β-adrenergic agonists mediate enhancement of β1- adrenergic receptor N-terminal cleavage and stabilization in vivo and in vitro

Molecular Pharmacology

Volumn 83, Issue 1, 2013, Pages 129-141

  Hakalahti, Anna E ^a   Khan, Hamayun ^a   Vierimaa, Miia M ^a   Pekkala, Emilia H ^a   Lackman, Jarkko J ^a   Ulvila, Johanna ^a   Kerkelä, Risto ^a   Petäjä Repo, Ulla E ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADENYLATE CYCLASE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; CELL SURFACE RECEPTOR; CHAPERONE; ISOPRENALINE; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PINDOLOL; PROPRANOLOL; TIMOLOL;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN STABILITY; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANIMALS, NEWBORN; CELL MEMBRANE; CYCLIC AMP; HEK293 CELLS; HUMANS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN PRECURSORS; PROTEIN STABILITY; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 84871539090     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.080440     Document Type: Article

References (42)

1. Aarons RD and Molinoff PB (1982) Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol. J Pharmacol Exp Ther 221:439-443. (Pubitemid 12122963)
2. Baker JG (2005) The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 144:317-322.
3. Baker JG, Hall IP, and Hill SJ (2003) Agonist actions of "β-blockers" provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol Pharmacol 63:1312-1321. (Pubitemid 36627226)
4. Bristow MR (2000) β-adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569.
5. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, and Jamieson S (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297-309. (Pubitemid 17178124)
6. Caron G, Steyaert G, Pagliara A, Reymond F, Crivori P, Gaillard P, Carrupt PA, Avdeef A, Comer J, Box KJ, et al. (1999) Structure-lipophilicity relationships of neutral and protonated β-blockers. Part I. Intra- and intermolecular effects in isotropic solvent systems. Helv Chim Acta 82:1211-1222. (Pubitemid 29402121)
7. Chen Y, Chen C, Wang Y, and Liu-Chen LY (2006) Ligands regulate cell surface level of the human κ opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists. J Pharmacol Exp Ther 319:765-775.
8. 1-receptor transgenic mice. Mol Pharmacol 60:712-717.
9. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
10. 1-adrenergic receptor is subject to constitutive and regulated N-terminal cleavage. J Biol Chem 285:28850-28861.
11. Hellenbrecht D, Lemmer B, Wiethold G, and Grobecker H (1973) Measurement of hydrophobicity, surface activity, local anaesthesia, and myocardial conduction velocity as quantitative parameters of the non-specific membrane affinity of nine β-adrenergic blocking agents. Naunyn Schmiedebergs Arch Pharmacol 277:211-226.
12. Henry AG, White IJ, Marsh M, von Zastrow M, and Hislop JN (2011) The role of ubiquitination in lysosomal trafficking of δ-opioid receptors. Traffic 12:170-184.
13. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, and Klotz KN (2004) Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369:151-159. (Pubitemid 38270770)
14. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, and Muramatsu I (2007) Different changes of plasma membrane β-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci 81:399-404. (Pubitemid 47077434)
15. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
16. 1-adrenoceptor dimerization and trafficking by pharmacological chaperones. Traffic 10:1019-1033.
17. Kuryatov A, Luo J, Cooper J, and Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors. Mol Pharmacol 68:1839-1851. (Pubitemid 41654365)
18. Lagerström MC and Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339-357.
19. Lattion A, Abuin L, Nenniger-Tosato M, and Cotecchia S (1999) Constitutively active mutants of the beta1-adrenergic receptor. FEBS Lett 457:302-306. (Pubitemid 29414711)
20. Leskelä TT, Markkanen PMH, Alahuhta IA, Tuusa JT, and Petäjä-Repo UE (2009) Phe27Cys polymorphism alters the maturation and subcellular localization of the human δ opioid receptor. Traffic 10:116-129.
21. Leskelä TT, Markkanen PMH, Pietilä EM, Tuusa JT, and Petäjä-Repo UE (2007) Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum. J Biol Chem 282:23171-23183.
22. 1-adrenergic receptor to agonist-mediated down-regulation. Role of the C terminus in determining β-subtype degradation. J Biol Chem 278:39773-39781.
23. Maisel AS, Motulsky HJ, and Insel PA (1987) Propranolol treatment externalizes β-adrenergic receptors in guinea pig myocardium and prevents further externalization by ischemia. Circ Res 60:108-112. (Pubitemid 17056936)
24. Michel MC, Pingsmann A, Beckeringh JJ, Zerkowski HR, Doetsch N, and Brodde OE (1988) Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment. Br J Pharmacol 94:685-692.
25. Milligan G and Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474.
26. Milting H, Scholz C, Arusoglu L, Freitag M, Cebulla R, Jaquet K, Körfer R, Lewinski D, Kassner A, and Brodde OE et al. (2006) Selective upregulation of β1-adrenergic receptors and dephosphorylation of troponin I in end-stage heart failure patients supported by ventricular assist devices. J Mol Cell Cardiol 41:441-450. (Pubitemid 44344275)
27. 1-adrenergic receptor. Proc Natl Acad Sci USA 108:8228-8232.
28. Petäjä-Repo UE, Hogue M, Bhalla S, Laperrière A, Morello JP, and Bouvier M (2002) Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J 21:1628-1637. (Pubitemid 34614619)
29. Petäjä-Repo UE, Hogue M, Laperrière A, Walker P, and Bouvier M (2000) Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human d opioid receptor. J Biol Chem 275:13727-13736. (Pubitemid 30257444)
30. Petäjä-Repo UE, Hogue M, Leskelä TT, Markkanen PMH, Tuusa JT, and Bouvier M (2006) Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human δ opioid receptor. J Biol Chem 281:15780-15789. (Pubitemid 43848468)
31. Plante E, Lachance D, Gaudreau M, Drolet MC, Roussel E, Arsenault M, and Couet J (2004) Effectiveness of β-blockade in experimental chronic aortic regurgitation. Circulation 110:1477-1483. (Pubitemid 39238027)
32. Rockman HA, Koch WJ, and Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212. (Pubitemid 34059526)
33. 2- adrenergic receptors. Mol Pharmacol 49:752-760.
34. Satwani S, Dec GW, and Narula J (2004) β-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 9:243-255. (Pubitemid 40130011)
35. 1-adrenergic receptor in a detergent-resistant form. Proc Natl Acad Sci USA 105:877-882.
36. 2-adrenergic receptors. J Biol Chem 275:29082-29090.
37. 2-adrenergic receptors. Cardiovasc Drugs Ther 13:123-126.
38. 2-adrenergic receptors in Chinese hamster fibroblasts. Mol Pharmacol 41:542-548.
39. Tokola H, Salo K, Vuolteenaho O, and Ruskoaho H (1994) Basal and acidic fibroblast growth factor-induced atrial natriuretic peptide gene expression and secretion is inhibited by staurosporine. Eur J Pharmacol 267:195-206.
40. Van Craenenbroeck K, Clark SD, Cox MJ, Oak JN, Liu F, and Van Tol HHM (2005) Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis. J Biol Chem 280:19350-19357. (Pubitemid 41379642)
41. 1-adrenergic receptor. Nature 469:241-244.
42. 1-adrenergic G-protein-coupled receptor. Nature 454:486-491.